WO2016153957A3 - Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases - Google Patents
Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases Download PDFInfo
- Publication number
- WO2016153957A3 WO2016153957A3 PCT/US2016/023021 US2016023021W WO2016153957A3 WO 2016153957 A3 WO2016153957 A3 WO 2016153957A3 US 2016023021 W US2016023021 W US 2016023021W WO 2016153957 A3 WO2016153957 A3 WO 2016153957A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fumarates
- compositions
- treatment
- methods
- intravenous administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020177029928A KR20170138437A (en) | 2015-03-20 | 2016-03-18 | Method and composition for intravenous administration of fumarate for the treatment of neurological diseases |
EA201792076A EA201792076A1 (en) | 2015-03-20 | 2016-03-18 | METHODS AND COMPOSITIONS FOR INTRAVENOUS ADMINISTRATION OF FUMARATES FOR THE TREATMENT OF NEUROLOGICAL DISEASES |
JP2017549232A JP2018508559A (en) | 2015-03-20 | 2016-03-18 | Methods and compositions for intravenous administration of fumarate esters for the treatment of nervous system disorders |
AU2016235743A AU2016235743A1 (en) | 2015-03-20 | 2016-03-18 | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases |
CN201680028617.1A CN107666905A (en) | 2015-03-20 | 2016-03-18 | Fumarate is applied to treat the method and composition of sacred disease for intravenous |
MX2017012239A MX2017012239A (en) | 2015-03-20 | 2016-03-18 | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases. |
US15/559,265 US20180289655A1 (en) | 2015-03-20 | 2016-03-18 | Methods and Compositions for the Intravenous Administration of Fumarates for the Treatment of Neurological Diseases |
EP16715662.9A EP3270895A2 (en) | 2015-03-20 | 2016-03-18 | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases |
CA2979544A CA2979544A1 (en) | 2015-03-20 | 2016-03-18 | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases |
IL254576A IL254576A0 (en) | 2015-03-20 | 2017-09-18 | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases |
HK18104073.2A HK1244680A1 (en) | 2015-03-20 | 2018-03-23 | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562136431P | 2015-03-20 | 2015-03-20 | |
US62/136,431 | 2015-03-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016153957A2 WO2016153957A2 (en) | 2016-09-29 |
WO2016153957A3 true WO2016153957A3 (en) | 2016-11-10 |
Family
ID=55702079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/023021 WO2016153957A2 (en) | 2015-03-20 | 2016-03-18 | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases |
Country Status (15)
Country | Link |
---|---|
US (1) | US20180289655A1 (en) |
EP (1) | EP3270895A2 (en) |
JP (1) | JP2018508559A (en) |
KR (1) | KR20170138437A (en) |
CN (1) | CN107666905A (en) |
AR (1) | AR104029A1 (en) |
AU (1) | AU2016235743A1 (en) |
CA (1) | CA2979544A1 (en) |
EA (1) | EA201792076A1 (en) |
HK (1) | HK1244680A1 (en) |
IL (1) | IL254576A0 (en) |
MA (1) | MA41785A (en) |
MX (1) | MX2017012239A (en) |
TW (1) | TW201642847A (en) |
WO (1) | WO2016153957A2 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005023241A1 (en) * | 2003-09-09 | 2005-03-17 | Fumapharm Ag | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
WO2006037342A2 (en) * | 2004-10-08 | 2006-04-13 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
WO2008096271A2 (en) * | 2007-02-08 | 2008-08-14 | Ralf Gold | Neuroprotection in demyelinating diseases |
WO2013090799A1 (en) * | 2011-12-16 | 2013-06-20 | Biogen Idec Ma Inc. | Silicon-containing fumaric acid esters |
WO2013119677A1 (en) * | 2012-02-07 | 2013-08-15 | Biogen Idec Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
CN103768045A (en) * | 2013-10-30 | 2014-05-07 | 苏州大学附属第一医院 | Application of dimethyl fumarate to preparation of medicine for treating early brain injury (EBI) after subarachnoid hemorrhage (SAH) |
US20140179779A1 (en) * | 2012-12-21 | 2014-06-26 | Biogen Idec Ma Inc. | Deuterium Substituted Fumarate Derivatives |
US20150079180A1 (en) * | 2013-09-18 | 2015-03-19 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
WO2016074684A1 (en) * | 2014-11-11 | 2016-05-19 | Syddansk Universitet | Fumaric acid derivatives for medical use |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
DE19721099C2 (en) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Use of fumaric acid derivatives |
CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
WO2007042035A2 (en) | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
US20080089861A1 (en) | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
ES2916649T3 (en) * | 2007-02-08 | 2022-09-21 | Biogen Ma Inc | Compositions and uses for the treatment of multiple sclerosis |
EP2671891A3 (en) | 2008-06-27 | 2014-03-05 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
EP2650279A3 (en) | 2008-08-19 | 2014-02-12 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
EP3466420A1 (en) | 2009-04-29 | 2019-04-10 | Biogen MA Inc. | Dimethyl fumarate for the treatment of friedreich ataxia |
EP2533634B1 (en) | 2010-02-12 | 2015-10-21 | Biogen MA Inc. | Neuroprotection in demyelinating diseases |
JP5072128B2 (en) * | 2011-03-31 | 2012-11-14 | 株式会社ワコール | Clothing with cup |
WO2013022882A1 (en) | 2011-08-08 | 2013-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Combination therapy for treatment of inflammatory demyelinating disease |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
US20140057918A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof |
US9868690B2 (en) | 2012-12-21 | 2018-01-16 | Ratiopharm Gmbh | Prodrugs of monomethyl fumarate (MMF) |
US10085955B2 (en) | 2013-01-08 | 2018-10-02 | Pathologica Llc | Methods and compositions for treatment of demyelinating diseases |
US10905663B2 (en) | 2013-03-05 | 2021-02-02 | The University Of Chicago | Treatment of demyelinating disorders |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
-
2016
- 2016-03-17 MA MA041785A patent/MA41785A/en unknown
- 2016-03-18 EP EP16715662.9A patent/EP3270895A2/en not_active Withdrawn
- 2016-03-18 WO PCT/US2016/023021 patent/WO2016153957A2/en active Application Filing
- 2016-03-18 CN CN201680028617.1A patent/CN107666905A/en not_active Withdrawn
- 2016-03-18 JP JP2017549232A patent/JP2018508559A/en not_active Withdrawn
- 2016-03-18 TW TW105108578A patent/TW201642847A/en unknown
- 2016-03-18 KR KR1020177029928A patent/KR20170138437A/en not_active IP Right Cessation
- 2016-03-18 MX MX2017012239A patent/MX2017012239A/en unknown
- 2016-03-18 EA EA201792076A patent/EA201792076A1/en unknown
- 2016-03-18 AU AU2016235743A patent/AU2016235743A1/en not_active Withdrawn
- 2016-03-18 US US15/559,265 patent/US20180289655A1/en not_active Abandoned
- 2016-03-18 AR ARP160100749A patent/AR104029A1/en unknown
- 2016-03-18 CA CA2979544A patent/CA2979544A1/en not_active Abandoned
-
2017
- 2017-09-18 IL IL254576A patent/IL254576A0/en unknown
-
2018
- 2018-03-23 HK HK18104073.2A patent/HK1244680A1/en unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005023241A1 (en) * | 2003-09-09 | 2005-03-17 | Fumapharm Ag | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
WO2006037342A2 (en) * | 2004-10-08 | 2006-04-13 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
WO2008096271A2 (en) * | 2007-02-08 | 2008-08-14 | Ralf Gold | Neuroprotection in demyelinating diseases |
WO2013090799A1 (en) * | 2011-12-16 | 2013-06-20 | Biogen Idec Ma Inc. | Silicon-containing fumaric acid esters |
WO2013119677A1 (en) * | 2012-02-07 | 2013-08-15 | Biogen Idec Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
US20140179779A1 (en) * | 2012-12-21 | 2014-06-26 | Biogen Idec Ma Inc. | Deuterium Substituted Fumarate Derivatives |
US20150079180A1 (en) * | 2013-09-18 | 2015-03-19 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
CN103768045A (en) * | 2013-10-30 | 2014-05-07 | 苏州大学附属第一医院 | Application of dimethyl fumarate to preparation of medicine for treating early brain injury (EBI) after subarachnoid hemorrhage (SAH) |
WO2016074684A1 (en) * | 2014-11-11 | 2016-05-19 | Syddansk Universitet | Fumaric acid derivatives for medical use |
Non-Patent Citations (6)
Title |
---|
ANONYMOUS: "Hydroxypropylbetacyclodextrin", June 2009 (2009-06-01), pages 36 - 39, XP055303673, Retrieved from the Internet <URL:http://www.roquette.com/media/deliacms/media//62/6297-36fb33.pdf> [retrieved on 20160919] * |
ANONYMOUS: "Ligand: Effective Drug Delivery Solutions With Captisol", DRUG DEVELOPMENT & DELIVERY, vol. 13, no. 8, October 2013 (2013-10-01), pages 64 - 66, XP055303766 * |
GISA ELLRICHMANN ET AL: "Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease", PLOS ONE, vol. 6, no. 1, 31 January 2011 (2011-01-31), pages e16172, XP055301151, DOI: 10.1371/journal.pone.0016172 * |
JING X ET AL: "Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 acti", NEUROSCIENCE, vol. 286, 29 November 2014 (2014-11-29), pages 131 - 140, XP029188354, ISSN: 0306-4522, DOI: 10.1016/J.NEUROSCIENCE.2014.11.047 * |
L YANG ET AL: "Neuroprotective effects of fumarates against MPTP mouse model of Parkinson's disease", SOCIETY FOR NEUROSCIENCE, vol. 43, November 2013 (2013-11-01), XP055301652 * |
TAE GEN SON ET AL: "Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia", JOURNAL OF NEUROCHEMISTRY, vol. 112, no. 5, March 2010 (2010-03-01), NEW YORK, NY, US, pages 1316 - 1326, XP055276327, ISSN: 0022-3042, DOI: 10.1111/j.1471-4159.2009.06552.x * |
Also Published As
Publication number | Publication date |
---|---|
CA2979544A1 (en) | 2016-09-29 |
CN107666905A (en) | 2018-02-06 |
US20180289655A1 (en) | 2018-10-11 |
EP3270895A2 (en) | 2018-01-24 |
JP2018508559A (en) | 2018-03-29 |
TW201642847A (en) | 2016-12-16 |
KR20170138437A (en) | 2017-12-15 |
AR104029A1 (en) | 2017-06-21 |
MA41785A (en) | 2018-01-23 |
MX2017012239A (en) | 2018-06-27 |
HK1244680A1 (en) | 2018-08-17 |
AU2016235743A1 (en) | 2017-10-12 |
IL254576A0 (en) | 2017-11-30 |
WO2016153957A2 (en) | 2016-09-29 |
EA201792076A1 (en) | 2018-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3448875A4 (en) | Compositions for the treatment of disease | |
EP3448987A4 (en) | Compositions for the treatment of disease | |
WO2016011306A3 (en) | Terminal modifications of polynucleotides | |
WO2017030823A3 (en) | Anti-tigit antibodies | |
WO2016033439A3 (en) | Compositions and methods for the treating an inflammatory disease or disorder | |
WO2016073693A3 (en) | Aadc polynucleotides for the treatment of parkinson's disease | |
WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
WO2016130920A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
EP3268086A4 (en) | Lsd for the treatment of alzheimer's disease | |
WO2018023072A3 (en) | Compounds and compositions and uses thereof | |
PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
MX2017009417A (en) | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof. | |
WO2017117070A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
EP3698649A4 (en) | Agent for preventing or ameliorating alzheimer's disease | |
MX2020000523A (en) | Isochroman compounds and uses thereof. | |
PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
MX2019001634A (en) | Amide compounds, pharmaceutical compositions thereof, and methods of using the same. | |
MX2018001592A (en) | Compositions and methods for treating and preventing neurodegenerative disorders. | |
IL270927B (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
WO2015109318A3 (en) | Therapeutic methods | |
EP3902539A4 (en) | Methods for treating parkinson's disease by administering resiniferatoxin | |
EP3554496A4 (en) | Methods and compositions for treating parkinson's disease | |
EP3261446A4 (en) | Methods and compositions for the treatment or prevention of parkinson's disease | |
EP3538095A4 (en) | Methods for treating parkinson's disease | |
WO2016153957A3 (en) | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16715662 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2979544 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 254576 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2017549232 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2017/012239 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2016235743 Country of ref document: AU Date of ref document: 20160318 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20177029928 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201792076 Country of ref document: EA |